Patent Grant
11517749
The present specification is directed toward modulating blood flow using electrical stimulation and, more specifically, to preventing, controlling and/or treating a hemorrhage by stimulating arteries, veins or nerves supplying the arteries and veins of a patient.
Trauma is the leading cause of death among US individuals younger than 44 years.
Hemorrhagic shock accounts for 30-40 percent of traumatic mortality. Bleeding is also the most common preventable cause of death on the battlefield. Applications of tourniquets to compressible hemorrhages results in a marked decrease in limb exsanguinations. According to the US army, hemorrhage not amenable to truncal tourniquets (also called non-compressible hemorrhage) is now the leading cause of preventable death. Some of the non-compressible hemorrhages occur due to bleeding into body cavities (such as the abdomen or chest), while others are caused by wounds in the junction between the trunk and the limbs or neck.
Effective prevention of blood loss in the pre-hospital arena offers the best opportunity to save soldiers with non-compressible injuries, therefore major efforts are undertaken to develop technologies for this unmet need. It has been demonstrated that thrombosis can be induced in a clamped blood vessel by minutes-long application of direct electric current. However, associated thermal damage precluded the use of this technology in clinical practice.
In addition, hemorrhage is a leading cause of death in operating rooms across the world. Approximately 4 in every 10,000 surgical patients, and 6 in every 10,000 patients receiving anesthesia, suffer fatal cardiac arrest within 30 postoperative days. Hemorrhage is responsible for 33% of these cardiac arrests.
Hence, there is a need for a quick and efficient method of preventing or controlling hemorrhage conditions in an organ without causing tissue damage. Such hemorrhage control would be applicable all hemorrhage situations and particularly in combat and operating room scenarios.
The present specification discloses a method of preventing an anticipated hemorrhage in an artery or vein of an upper limb of a patient using at least one electrode in electrical communication with a pulse generator, the method comprising: arranging the at least one electrode at a location proximate a surface of the patient's artery or vein, wherein said artery is at least one of a subclavian artery, an axillary artery, a deep brachial artery, a brachial artery, a radial artery, an ulnar artery, a deep palmar arch, and a superficial palmar arch or said vein is at least one of subclavian vein, axillary vein, cephalic vein, brachial vein, radial vein, ulnar vein, deep palmar arch, superficial palmar arch, basilic vein, median cubital vein, and median antebrachial vein and wherein said location is at least 1 cm upstream from a location of the anticipated hemorrhage; and causing the pulse generator to generate an electrical stimulus administered to the artery or the vein through the at least one electrode, wherein the electrical stimulus has a pulse duration, a pulse amplitude, and a pulse frequency and wherein said pulse duration, said pulse amplitude, and said pulse frequency are selected such that the electrical stimulus is effective to cause vasoconstriction in said artery or said vein and thereby prevent said anticipated hemorrhage.
Optionally, the pulse duration ranges from 1 μsec to 500 msec, the pulse amplitude ranges from 1 V to 250 V, and the pulse frequency ranges from 1 Hz to 100 kHz.
Optionally, the at least one electrode is at least one of a cuff electrode and a clamp electrode and arranging the at least one electrode comprises placing said cuff electrode or said clamp electrode in direct physical contact with said location.
Optionally, a radio-frequency (RF) receiver is coupled to said at least one electrode and a RF transmitter is coupled to said pulse generator and in wireless communication with said RF receiver and said method further comprises causing the pulse generator to generate, and wirelessly transmit, an electrical stimulus from the RF transmitter to the RF receiver to be administered by said at least one electrode.
The method may further comprise using a microprocessor operably connected to the pulse generator to selectively set said pulse duration, said pulse amplitude, and said pulse frequency.
The present specification also discloses a method of preventing an anticipated hemorrhage in an artery or vein of a lower limb of a patient using at least one electrode in electrical communication with a pulse generator, the method comprising: arranging the at least one electrode at a location proximate a surface of the patient's artery or vein, wherein said artery is at least one of a femoral artery, popliteal artery, anterior tibial artery, posterior tibial artery, peroneal artery, dorsalis pedis artery, and plantar arch or said vein is at least one of external iliac vein, femoral vein, perforating vein, great saphenous vein, small saphenous vein, anterior tibial vein, posterior tibial vein, and dorsal venous arch and wherein said location is at least 1 cm upstream from a location of an anticipated hemorrhage; and causing the pulse generator to generate an electrical stimulus administered to the artery or the vein through the at least one electrode, wherein the electrical stimulus has a pulse duration, a pulse amplitude, and a pulse frequency and wherein said pulse duration, said pulse amplitude, and said pulse frequency are selected such that the electrical stimulus is effective to cause vasoconstriction in said artery or said vein and thereby prevent said anticipated hemorrhage.
Optionally, the pulse duration ranges from 1 μsec to 500 msec, the pulse amplitude ranges from 1 V to 250 V, and the pulse frequency ranges from 1 Hz to 100 kHz.
Optionally, the at least one electrode is a cuff electrode or clamp electrode and arranging the at least one electrode comprises placing said cuff electrode or said clamp electrode in direct physical contact with said location.
Optionally, a radio-frequency (RF) receiver is coupled to said at least one electrode and a RF transmitter is coupled to said pulse generator and in wireless communication with said RF receiver, and said method further comprises causing the pulse generator to generate, and wirelessly send, an electrical stimulus from the RF transmitter to the RF receiver to be administered by said at least one electrode.
The method may further comprise using a microprocessor operably connected to the pulse generator to selectively set said pulse duration, said pulse amplitude, and said pulse frequency.
The present specification also discloses a method of controlling a hemorrhage in a patient in advance of a planned surgical procedure, the method comprising: initiating a surgery in an abdominal region of said patient; arranging at least one electrode of a stimulation apparatus at a location in electrical communication with a blood vessel upstream to, and supplying blood to, a blood vessel in said abdominal region before said hemorrhage develops; connecting said at least one electrode to an electrical pulse generator; identifying the hemorrhage during said surgical procedure; and causing the pulse generator to generate an electrical stimulus administered to the upstream blood vessel, wherein the electrical stimulus has a pulse duration, a pulse amplitude, and a pulse frequency and wherein said pulse duration, said pulse amplitude, and said pulse frequency are selected such that the electrical stimulus is effective to cause vasoconstriction of the upstream blood vessel and reduce blood flow to control the hemorrhage of the blood vessel in the abdominal region.
Optionally, the pulse duration ranges from 1 μsec to 500 msec, the pulse amplitude ranges from 1 V to 250 V, and the pulse frequency ranges from 1 Hz to 100 kHz.
Optionally, the at least one electrode is a cuff electrode or clamp electrode and arranging the at least one electrode comprises placing said cuff electrode or said clamp electrode in direct physical contact with said location.
Optionally, a radio-frequency (RF) receiver is coupled to said at least one electrode and a RF transmitter is coupled to said pulse generator and in wireless communication with said RF receiver, and said method further comprises causing the pulse generator to generate, and wirelessly send, an electrical stimulus from the RF transmitter to the RF receiver to be administered by said at least one electrode.
The method may further comprise using a microprocessor operably connected to the pulse generator to selectively set said pulse duration, said pulse amplitude, and said pulse frequency.
The present specification also discloses a method of preventing a hemorrhage in a patient in advance of a planned surgical procedure, the method comprising: initiating a surgery in an abdominal region of said patient, wherein initiating surgery is defined as exposing an area proximate a blood vessel in said abdominal region that is involved in said surgery; arranging at least one electrode of a stimulation apparatus at a location in electrical communication with a blood vessel upstream to, and supplying blood to, the blood vessel in said abdominal region before said hemorrhage develops; connecting said at least one electrode to an electrical pulse generator; proceeding with said surgery; prior to beginning a surgical technique in which an increased likelihood of the hemorrhage is anticipated, causing the pulse generator to generate an electrical stimulus administered to the upstream blood vessel for a predetermined period of time, wherein the electrical stimulus has a pulse duration, a pulse amplitude, and a pulse frequency and wherein said pulse duration, said pulse amplitude, and said pulse frequency are selected such that the electrical stimulus is effective to cause vasoconstriction of the upstream blood vessel and reduce blood flow to prevent the hemorrhage of the blood vessel in the abdominal region; and proceeding with said surgical technique.
Optionally, said predetermined period of time is equal to at least 30 seconds.
Optionally, said electrical stimulus is administered for at least 10 seconds during said surgical technique.
Optionally, said electrical stimulus is administered prior to beginning said surgical technique and during a remainder of the surgery.
Optionally, said at least one electrode is configured to remain within said abdominal region for a period of time ranging from 1 to 7 days and said electrical stimulus is administered post-operatively to treat a post-operative hemorrhage.
The present specification discloses a method of treating a hemorrhage in an artery or vein of an upper limb of a patient using at least one electrode in electrical communication with a pulse generator, the method comprising: arranging the at least one electrode at a location proximate a surface of the patient's artery or vein, wherein said artery is at least one of a subclavian artery, an axillary artery, a deep brachial artery, a brachial artery, a radial artery, an ulnar artery, a deep palmar arch, and a superficial palmar arch or said vein is at least one of subclavian vein, axillary vein, cephalic vein, brachial vein, radial vein, ulnar vein, deep palmar arch, superficial palmar arch, basilic vein, median cubital vein, and median antebrachial vein and wherein said location is at least 1 cm upstream from a location of the hemorrhage; and causing the pulse generator to generate an electrical stimulus administered to the artery or the vein through the at least one electrode, wherein the electrical stimulus has a pulse duration, a pulse amplitude, and a pulse frequency and wherein said pulse duration, said pulse amplitude, and said pulse frequency are selected such that the electrical stimulus is effective to cause vasoconstriction in said artery or said vein.
The pulse duration may range from 1 μsec to 500 msec, the pulse amplitude may range from 1 V to 250 V, and the pulse frequency may range from 1 Hz to 100 kHz.
Optionally, the at least one electrode is a cuff electrode or clamp electrode and arranging the at least one electrode comprises placing said cuff electrode or said clamp electrode in physical contact with said location.
Optionally, a radio-frequency (RF) receiver is coupled to said at least one electrode and a RF transmitter is coupled to said pulse generator and in wireless communication with said RF receiver and the method further comprises causing the pulse generator to generate, and wirelessly send, an electrical stimulus from the RF transmitter to the RF receiver to be administered by said at least one electrode.
Optionally, the method further comprises using a microprocessor operably connected to the pulse generator to selectively set said pulse duration, said pulse amplitude, and said pulse frequency.
The present specification also discloses a method of treating a hemorrhage in an artery or vein of a lower limb of a patient using at least one electrode in electrical communication with a pulse generator, the method comprising: arranging the at least one electrode at a location proximate a surface of the patient's artery or vein, wherein said artery is at least one of a femoral artery, popliteal artery, anterior tibial artery, posterior tibial artery, peroneal artery, dorsalis pedis artery, and plantar arch or said vein is at least one of external iliac vein, femoral vein, perforating vein, great saphenous vein, small saphenous vein, anterior tibial vein, posterior tibial vein, and dorsal venous arch and wherein said location is at least 1 cm upstream from a location of the hemorrhage; and causing the pulse generator to generate an electrical stimulus administered to the artery or the vein through the at least one electrode, wherein the electrical stimulus has a pulse duration, a pulse amplitude, and a pulse frequency and wherein said pulse duration, said pulse amplitude, and said pulse frequency are selected such that the electrical stimulus is effective to cause vasoconstriction in said artery or said vein.
The pulse duration may range from 1 μsec to 500 msec, the pulse amplitude may range from 1 V to 250 V, and the pulse frequency may range from 1 Hz to 100 kHz.
Optionally, the at least one electrode is a cuff electrode or clamp electrode and arranging the at least one electrode comprises placing said cuff electrode or said clamp electrode in physical contact with said location.
Optionally, a radio-frequency (RF) receiver is coupled to said at least one electrode and a RF transmitter is coupled to said pulse generator and in wireless communication with said RF receiver and the method further comprises causing the pulse generator to generate, and wirelessly send, an electrical stimulus from the RF transmitter to the RF receiver to be administered by said at least one electrode.
Optionally, the method further comprises using a microprocessor operably connected to the pulse generator to selectively set said pulse duration, said pulse amplitude, and said pulse frequency.
The present specification also discloses a method of preventing or treating a hemorrhage in a patient in advance of a planned surgical procedure, the method comprising: initiating a surgery in an abdominal region of said patient; arranging at least one electrode of a stimulation apparatus at a location in electrical communication with a blood vessel upstream to and supplying blood to a blood vessel in said abdominal region before a hemorrhage develops; connecting said at least one electrode to an electrical pulse generator; identifying a hemorrhage during said surgical procedure; and causing the pulse generator to generate an electrical stimulus administered to the upstream blood vessel, wherein the electrical stimulus has a pulse duration, a pulse amplitude, and a pulse frequency and wherein said pulse duration, said pulse amplitude, and said pulse frequency are selected such that the electrical stimulus is effective for causing vasoconstriction of the upstream blood vessel and reducing blood flow to prevent or control hemorrhage of the blood vessel involved in the abdominal region. The said pulse stimulus can be applied for at least 30 seconds before the onset of such hemorrhage, thus reducing the frequency or severity of such hemorrhage.
The pulse duration may range from 1 μsec to 500 msec, the pulse amplitude may range from 1 V to 250 V, and the pulse frequency may range from 1 Hz to 100 kHz.
Optionally, at least one electrode is a cuff electrode or clamp electrode and arranging the at least one electrode comprises placing said cuff electrode or said clamp electrode in physical contact with said location.
Optionally, a radio-frequency (RF) receiver is coupled to said at least one electrode and a RF transmitter is coupled to said pulse generator and in wireless communication with said RF receiver and said method further comprises causing the pulse generator to generate, and wirelessly send, an electrical stimulus from the RF transmitter to the RF receiver to be administered by said at least one electrode.
Optionally, the method further comprises using a microprocessor operably connected to the pulse generator to selectively set said pulse duration, said pulse amplitude, and said pulse frequency.
The present specification also discloses a method of treating a hemorrhage in a body organ of a patient, the method comprising: arranging at least one electrode of a stimulation apparatus proximate an artery supplying blood to the body organ, a vein supplying blood from the body organ, a nerve supplying said artery or said vein, or a wall of said body organ; connecting said at least one electrode to an electrical pulse generator; and causing the pulse generator to generate an electrical stimulus administered to the artery, vein, nerve, or wall of said body organ through the at least one electrode, wherein the electrical stimulus is effective for causing vasoconstriction and reducing blood flow to said body organ. Optionally, the electrode of the stimulation apparatus is in electrical communication with an artery supplying blood to the body organ, a vein supplying blood from the body organ, a nerve supplying said artery or said vein, or a wall of said body organ.
The electrical stimulus may have a pulse duration ranging from 1 μsec to 500 msec, a pulse amplitude ranging from 1 V to 250 V, and a pulse frequency ranging from 1 Hz to 100 kHz.
Optionally, the electrode is a cuff electrode or clamp electrode and arranging the at least one electrode proximate an artery, a vein, a nerve supplying an artery or vein, or a wall of said body organ comprises placing said cuff electrode or said clamp electrode in physical contact with said artery, vein, nerve, or wall.
Optionally, a radio-frequency (RF) receiver is coupled to said at least one electrode and a RF transmitter is coupled to said pulse generator and in wireless communication with said RF receiver, and said method further comprises the step of causing the pulse generator to generate and wirelessly send an electrical stimulus from the RF transmitter to the RF receiver to be administered by said at least one electrode.
Optionally, the apparatus further comprises a microprocessor operably connected to the pulse generator, wherein at least one parameter of the stimulus is controlled by the microprocessor and wherein said method further comprises using the microprocessor to control said pulse generator to generate an electrical stimulus.
The present specification also discloses a method of modulating blood flow to an organ of a patient, the method comprising: providing an apparatus comprising at least one electrode operably connected to a pulse generator; placing the at least one electrode in electrical communication with an artery supplying blood to the organ, a vein supplying blood from the organ, or a nerve supplying said artery or said vein; and causing the pulse generator to generate an electrical stimulus administered to the artery, vein, or nerve through the at least one electrode, wherein the electrical stimulus is effective for modulating blood flow to the organ.
The stimulus may be effective for constricting the artery or vein.
The electrical stimulus may have a pulse duration ranging from 1 μsec to 500 msec, a pulse amplitude ranging from 1 V to 250 V, and a pulse frequency ranging from 1 Hz to 100 kHz.
Optionally, the electrode is a cuff electrode or clamp electrode and arranging the at least one electrode proximate an artery, a vein, or nerve supplying an artery or vein comprises placing said cuff electrode or said clamp electrode in physical contact with said artery, vein, or nerve.
Optionally, a radio-frequency (RF) receiver is coupled to said at least one electrode and a RF transmitter is coupled to said pulse generator and in wireless communication with said RF receiver, and said method further comprises the step of causing the pulse generator to generate and wirelessly send an electrical stimulus from the RF transmitter to the RF receiver to be administered by said at least one electrode.
Optionally, the apparatus further comprises a microprocessor operably connected to the pulse generator, wherein at least one parameter of the stimulus is controlled by the microprocessor and wherein said method further comprises using the microprocessor to control said pulse generator to generate an electrical stimulus.
The present specification also discloses a method of modulating blood flow to an organ of a patient, the method comprising: providing an apparatus comprising at least one electrode operably connected to a pulse generator; placing the at least one electrode in electrical communication with a wall of the organ; and causing the stimulus generator to generate an electrical stimulus administered proximate the wall through the at least one electrode, wherein the electrical stimulus is effective for modulating blood flow to the organ.
The stimulus may be effective for constricting or dilating one or more blood vessels within the wall of the organ, thus altering the blood flow through the said blood vessel.
Optionally, a radio-frequency (RF) receiver is coupled to said at least one electrode and a RF transmitter is coupled to said pulse generator and in wireless communication with said RF receiver, and said method further comprises the step of causing the pulse generator to generate and wirelessly send an electrical stimulus from the RF transmitter to the RF receiver to be administered by said at least one electrode.
Optionally, the apparatus further comprises a microprocessor operably connected to the pulse generator, wherein at least one parameter of the stimulus is controlled by the microprocessor and wherein said method further comprises using the microprocessor to control said pulse generator to generate an electrical stimulus.
The present specification also discloses a method of controlling blood flow to an organ comprising the steps of: arranging at least one electrode proximate to an artery, a vein or a nerve supplying an artery and vein and activating said electrode to provide an electrical stimulus thereto, wherein said electrical stimulus is effective in controlling the blood flow to the organ.
The present specification also disclose a method of controlling blood flow to an organ comprising the steps of: arranging at least one electrode proximate to an artery supplying blood to the organ, a vein supplying blood from the organ, or a nerve supplying said artery or said vein and activating said electrode to provide a first electrical stimulus thereto, wherein said the first electrical stimulus is effective in decreasing the blood flow to the organ to prevent a hemorrhage and activating said electrode to provide a second electrical stimulus thereto, wherein said the second electrical stimulus is effective in decreasing the blood flow to the organ to treat a hemorrhage.
The present specification also discloses a method of preventing intraoperative bleeding comprising the steps of: arranging at least one electrode proximate or in electrical contact with an artery, a vein or a nerve supplying an artery and vein and activating said electrode to provide an electrical stimulus thereto, wherein said electrical stimulus is effective in controlling the blood flow in the artery or the vein.
The present specification also discloses a method of treating intraoperative bleeding comprising the steps of: arranging at least one electrode proximate to an artery, a vein or a nerve supplying an artery and vein and activating said electrode to provide an electrical stimulus thereto, wherein said electrical stimulus is effective in controlling the blood flow in the artery or the vein.
The present specification also discloses a method for generating an electrical signal for vascular stimulation, the method comprising: identifying a first electrical stimulation reaction threshold for vasoconstriction in a patient; identifying a second reaction threshold for thrombosis in the patient; and electrically stimulating a vascular structure with an electrical stimulation signal that is below said identified second reaction threshold for thrombosis and above said first reaction threshold for vasoconstriction such that the stimulus generates a predominance of vasoconstriction over thrombosis.
The present specification also discloses a method of controlling blood flow to an organ by arranging at least one electrode of a stimulation apparatus in electrical communication with an artery, a vein, a nerve supplying an artery or vein, or a wall of said body organ; connecting said at least one electrode to an electrical pulse generator; and causing the pulse generator to generate an electrical stimulus administered to the artery, vein, nerve, or wall of said body organ through the at least one electrode, wherein the electrical stimulus is effective for changing blood flow to said body organ where the change in the blood flow is maintained for at least 1 minute after the cessation of the electrical stimulation.
The above summary of the present invention is not intended to describe each disclosed embodiment or every implementation of the present invention. The description that follows more particularly exemplifies illustrative embodiments. However, embodiments other than those expressly described are possible and may be made, used, and/or practiced under circumstances and/or conditions that are the same or different from the circumstances and/or conditions described in connection with the illustrative embodiments. In several places throughout the application, guidance is provided through lists of examples, which examples can be used in various combinations. In each instance, the recited list serves only as a representative group and should not be interpreted as an exclusive list.
The aforementioned and other embodiments of the present specification shall be described in greater depth in the drawings and detailed description provided below.
These and other features and advantages of the present invention will be further appreciated, as they become better understood by reference to the detailed description when considered in connection with the accompanying drawings:
The present invention provides methods of treating a gastrointestinal (GI) disorder. Very generally, the treatment involves controlling the function of the gastrointestinal system by regulating the blood flow through the tissues and organs of the gastrointestinal tract. Generally, the control of blood flow through the GI tract is accomplished by administering a stimulus to either the vessels that supply blood to the GI tract or nerves that control those blood vessels.
The present specification is directed towards multiple embodiments. The following disclosure is provided in order to enable a person having ordinary skill in the art to practice the invention. Language used in this specification should not be interpreted as a general disavowal of any one specific embodiment or used to limit the claims beyond the meaning of the terms used therein. The general principles defined herein may be applied to other embodiments and applications without departing from the spirit and scope of the invention. Also, the terminology and phraseology used is for the purpose of describing exemplary embodiments and should not be considered limiting. Thus, the present invention is to be accorded the widest scope encompassing numerous alternatives, modifications and equivalents consistent with the principles and features disclosed. For purpose of clarity, details relating to technical material that is known in the technical fields related to the invention have not been described in detail so as not to unnecessarily obscure the present invention.
“Treat,” “treatment,” and variations thereof refer to any reduction in the extent, frequency, or severity of one or more symptoms or signs associated with a condition.
“Duration” and variations thereof refer to the time course of a prescribed treatment, from initiation to conclusion, whether the treatment is concluded because the condition is resolved or the treatment is suspended for any reason. Over the duration of treatment, a plurality of treatment periods may be prescribed during which one or more prescribed stimuli are administered to the subject.
“Period” refers to the time over which a “dose” of stimulation is administered to a subject as part of the prescribe treatment plan.
The term “and/or” means one or all of the listed elements or a combination of any two or more of the listed elements.
In the description and claims of the application, each of the words “comprise” “include” and “have”, and forms thereof, are not necessarily limited to members in a list with which the words may be associated. It should be noted herein that any feature or component described in association with a specific embodiment may be used and implemented with any other embodiment unless clearly indicated otherwise.
Unless otherwise specified, “a,” “an,” “the,” “one or more,” and “at least one” are used interchangeably and mean one or more than one.
For any method disclosed herein that includes discrete steps, the steps may be conducted in any feasible order. And, as appropriate, any combination of two or more steps may be conducted simultaneously.
Also herein, the recitations of numerical ranges by endpoints include all numbers subsumed within that range (e.g., 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, 5, etc.). Unless otherwise indicated, all numbers expressing quantities of components, molecular weights, and so forth used in the specification and claims are to be understood as being modified in all instances by the term “about.” Accordingly, unless otherwise indicated to the contrary, the numerical parameters set forth in the specification and claims are approximations that may vary depending upon the desired properties sought to be obtained by the present invention. At the very least, and not as an attempt to limit the doctrine of equivalents to the scope of the claims, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques.
Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the invention are approximations, the numerical values set forth in the specific examples are reported as precisely as possible. All numerical values, however, inherently contain a range necessarily resulting from the standard deviation found in their respective testing measurements.
Appetite Modulation
Mesenteric blood supply is important for proper functioning of the gastrointestinal system and is important for the digestion of all nutrients. Interrupting the mesenteric vascular supply may impair digestion of various nutrients, including fat digestion, and therefore can be helpful in managing conditions of over-nutrition including, for example, obesity.
Referring now to the various views of the accompanying drawings,
The mesenteric arteries constitute the major arterial blood supply of the gastrointestinal system and the mesenteric veins constitute the major system draining the blood from the gastrointestinal system. The flow of the blood to and from the gastrointestinal system is controlled by the tonic contraction and relaxation of the smooth muscle in the blood vessels of the mesenteric vascular system. The blood flow in the fasting state maintains the viability of the gastrointestinal tract. In the fed state, the work of the gastrointestinal tract increases and requires a corresponding increased need for oxygen and nutrients to the gastrointestinal system. The increased need for oxygen and nutrients is met by increasing the supply of blood to the gastrointestinal tract, accomplished by dilating the mesenteric arteries. This phenomenon of increasing the energy requirement of the gastrointestinal tract after a eating is known as the specific dynamic action of food. In situations of dehydration or hemorrhage, blood is shunted away from the gastrointestinal tract to other vital organs. This decrease in blood supply to the gastrointestinal tract is accomplished by the constriction of the mesenteric arteries. Subjects having a blockage in the mesenteric arteries due to, for example, atherosclerotic artery disease can have difficulty increasing the blood supply to the gastrointestinal tract that is required to process and digest food after a meal. These subjects can develop pain, loss of appetite, and weight loss.
The methods described herein involve controlling a subject's appetite, inducing satiety, and/or inducing weight loss by regulating the blood flow to the intestinal tract and more specifically by regulating the specific dynamic action of food—i.e., the meal-induced increase in the blood supply to the gastrointestinal tract—through stimulation of the mesenteric vasculature and/or nerves supplying the mesenteric vasculature.
The methods described herein can also be applied to treating certain cardiovascular conditions or indications, including angina, chest tightening, unstable angina, stable angina, coronary artery disease, atherosclerotic disease, heart failure or myocardial infarction. By reducing the blood flow to the intestinal tract and more specifically by minimizing the increase of blood flow to the gastrointestinal tract due to the specific dynamic action of food, the present invention can also help treat the aforementioned cardiovascular conditions. Specifically, reducing blood flow in the patient's mesenteric circulation or peripheral circulation increases blood flow in the coronary circulation or cerebral circulation, thereby reducing or eliminating symptoms related to the aforementioned disorders.
In order to reduce the meal-induced blood flow to the gastrointestinal tract, an electrical, chemical, or mechanical stimulus effective for treating a gastrointestinal condition is applied to one or more target locations in the celiac artery 11, superior mesenteric artery 12, inferior mesenteric artery 13, internal iliac artery 16, external iliac artery 17, superior mesenteric vein 18, or inferior mesenteric vein 19, or the nerves 15 supplying the celiac artery 11, superior mesenteric artery 12, inferior mesenteric artery 13, internal iliac artery 16, external iliac artery 17, superior mesenteric vein 18, or inferior mesenteric vein 19. As used herein, a stimulus “effective for treating a gastrointestinal condition” includes stimulation sufficient to result in, for example, contraction of at least one or more of the celiac artery 11, superior mesenteric artery 12, inferior mesenteric artery 13, internal iliac artery 16, external iliac artery 17, superior mesenteric vein 18, or inferior mesenteric vein 19, thus reducing the flow of blood into the gastrointestinal tract.
A reduction in the blood flow to the gastrointestinal tract can interrupt gastrointestinal function such as, for example, digestion and absorption of nutrients such as, for example, fat. The stimulation may result in curbing a subject's appetite and/or inducing satiety, anorexia, and/or weight loss in a subject due to discomfort incurred by a patient upon ingestion and, accordingly, stimulation of the target locations. Thus, in certain embodiments, a stimulus “effective for treating a gastrointestinal condition” can include stimulation that may, for example, curb a subject's appetite and/or induce satiety, anorexia, and/or weight loss in a subject. In other embodiments, a stimulus “effective for treating a gastrointestinal condition” can include a stimulus effective for treating a condition secondary to obesity such as, for example, diabetes, hypertension, heart attack, stroke, dyslipidemia, sleep apnea, Pickwick Ian Syndrome, asthma, lower back and disc disease, weight-bearing osteo-arthritis of the hips, knees, ankles and feet, thrombophlebitis and pulmonary emboli, intertriginous dermatitis, urinary stress incontinence, gastroesophageal reflux disease (GERD), gallstones, sclerosis, carcinoma of the liver, infertility, cancer of the uterus, and/or cancer of the breast.
In one embodiment, at least one electrode set is placed in the mesenteric circulation near one or more of the celiac artery 11, superior mesenteric artery 12, inferior mesenteric artery 13, internal iliac artery 16, external iliac artery 17, superior mesenteric vein 18 or inferior mesenteric vein 19 or a branch of the celiac artery 11, superior mesenteric artery 12, inferior mesenteric artery 13, internal iliac artery 16, external iliac artery 17, superior mesenteric vein 18 or inferior mesenteric vein 19. Each electrode set includes at least one active electrode and at least one ground electrode. The electrode set may be arranged in any pattern that produces the desired stimulation to the celiac artery 11, superior mesenteric artery 12, inferior mesenteric artery 13, internal iliac artery 16, external iliac artery 17, superior mesenteric vein 18 or inferior mesenteric vein 19, or a branch of the celiac artery 11, superior mesenteric artery 12, inferior mesenteric artery 13, internal iliac artery 16, external iliac artery 17, superior mesenteric vein 18 or inferior mesenteric vein 19 such as a circumferential pattern, along a longitudinal axis, an irregular pattern, or other placement.
In a preferred embodiment, the celiac artery or a branch of a celiac artery is stimulated by itself or in combination with at least one other vascular structure. In another preferred embodiment, the celiac artery or a branch of a celiac artery is stimulated in combination with the SMA or a branch of SMA. In yet another preferred embodiment, at least two vascular structures, such as arteries, veins, or nerves associated with the arteries or veins, are stimulated concurrently or in a predefined sequence, or a combination of both. The predefined sequence can be in rapid or slow succession.
In some embodiments, the stimulator device 26 could be triggered manually by, for example, a medical professional, a caregiver, or the subject. Alternatively, a set of sensing electrodes 24 can detect one of the physiological parameters associated with eating a meal and generate a signal to deliver an electrical stimulus to the celiac artery 11, which can result in meal-induced celiac vasoconstriction, thereby curbing a subject's appetite and/or inducing anorexia, satiety, and/or weight loss in the subject. Exemplary physiological parameters are identified below.
In some embodiments, the stimulator devices 36, 36′ can be triggered manually by, for example, a medical professional, a caregiver, or the subject. Alternatively, a set of sensing electrodes 34 can detect one of the physiological parameters associated with a meal and generate a signal to cause superior mesenteric artery 12 or superior mesenteric vein 18 vasoconstriction, and decrease blood supply to middle part of the gastrointestinal system. This can induce feelings of fullness, satiety and/or reduced appetite.
In some embodiments, the stimulator device 46, 46′ can be triggered manually by, for example, a medical professional, a caregiver, or the subject. Alternatively, a set of sensing electrodes 44 can detect one of the physiological parameters associated with a meal and generate a signal to cause the delivery of an electrical stimulus which can cause inferior mesenteric artery 13 or inferior mesenteric vein 19 vasoconstriction, and decrease blood supply to the lower gastrointestinal system.
In each embodiment described above, the decrease in blood supply to the gastrointestinal (GI) system—whether to the upper GI system as depicted, for example, in
Also in each embodiment, the electrode set 21 can provide an electrical stimulus of from about 1 microampere (μAmp) up to about 100 Amp, although the methods described herein may be practiced by providing an electrical stimulation outside of this range. Typically, the amplitude of the electrical stimulus can be from about 1 milliamp (mAmp) to about 10 Amp. In some embodiments, the electrical stimulus can be less than about 10 amp such as, for example, less than 1 amp. In certain embodiments, the amplitude of the electrical stimulus can be from about 5 mAmp to about 100 mAmp such as, for example, 10 mAmp. Also, certain treatments may include multiple electrical stimuli having any combination of varying amplitudes.
An electrical stimulus “dose” can be provided continuously or intermittently. For example, an electrical stimulus may be provided one time, may be provided continuously for a prescribed period, or may be provided in a series of intermittent stimuli over a prescribed period. The prescribed period may be such as, for example, from about 1 millisecond (msec) to about one hour. Intermittent electrical stimuli may be provided at regular, prescribed intervals within the treatment period. For example, intermittent electrical stimuli, one second in length, may be provided for, for example, one hour. In other cases, intermittent electrical stimuli may be provided on an “as needed” basis. Also, certain treatments may include multiple electrical stimuli provided over any combination of varying treatment periods.
An electrical stimulus may have any pattern necessary to produce the desired result, including a square, rectangular, sinusoidal, or saw-tooth shape. Also, certain treatments may include multiple electrical stimuli including any combination of patterns.
The frequency of the electrical stimulus can be in the range of approximately 1 microHertz (μHz) to about 1 megaHertz (MHz), although the methods described herein may be practiced by administering electrical stimuli having a frequency outside of this range. Typically, an electrical stimulus may have a frequency of about 1 mHz to about 1 MHz such as, for example, a frequency of from about 0.1 Hz to about 10 Hz. In certain embodiments, an electrical stimulus may be administered at a frequency of about 1 Hz. Also, certain treatments may include multiple electrical stimuli including any combination of frequencies.
Electrodes of the electrode set 21 can be placed in the tunica intima, tunica media, tunica externa and/or adventitia of the celiac artery 11, superior mesenteric artery 12, inferior mesenteric artery 13, internal iliac artery 16, external iliac artery 17, superior mesenteric vein 18, and/or inferior mesenteric vein 19. Alternatively, electrodes of the electrode set 21 may be placed on nerves 15 supplying the celiac artery 11, superior mesenteric artery 12, inferior mesenteric artery 13, internal iliac artery 16, external iliac artery 17, superior mesenteric vein 18, and/or inferior mesenteric vein 19 or a branch of the celiac artery 11, superior mesenteric artery 12, inferior mesenteric artery 13, internal iliac artery 16, external iliac artery 17, superior mesenteric vein 18, and/or inferior mesenteric vein 19. Alternatively, electrodes of the electrode set 21 may be placed on nerves 15 supplying the celiac artery 11, superior mesenteric artery 12, inferior mesenteric artery 13, internal iliac artery 16, external iliac artery 17, superior mesenteric vein 18, and/or inferior mesenteric vein 19. The number of electrodes in a set, as well as the number of electrode sets, employed for treatment of a particular condition may be influenced by factors such as, for example, the size of the electrodes, the prescribed stimulus amplitude, frequency, and/or pattern, and the size of the desired placement area.
An electrical stimulus may be triggered by a transmitter external to the human body, similar to a remote transmitter for a cardiac pacemaker. With appropriate stimulus amplitude, frequency, and pattern, and appropriate treatment periods and duration, gastrointestinal diseases such as obesity can be treated without causing permanent injury to the surrounding tissue or organs.
A chemical stimulus “dose” can be provided continuously or intermittently. For example, a chemical stimulus may be provided one time, may be provided continuously for a prescribed period, or may be provided in a series of intermittent stimuli over a prescribed period. The prescribed period may be such as, for example, from about 0.1 μL/hr to about 1 L/min such as, for example, 0.1-10 μL/min. Intermittent chemical stimuli may be provided at regular, prescribed intervals within the treatment period. For example, intermittent chemical stimuli may be provided at a rate of 0.1 μL/min for 30 minutes. In other cases, intermittent chemical stimuli may be provided on an “as needed” basis. Also, certain treatments may include multiple chemical stimuli provided over any combination of varying treatment periods.
In some embodiments, a signal to deliver the vasoactive or neuroactive chemical may be triggered manually by, for example, a medical professional, a caregiver, or the subject. Alternatively, a set of sensing electrodes can detect one of the physiological parameters associated with a meal and generate a signal to cause the delivery of the chemical stimulus, which can affect blood supply to the gastrointestinal tract. However triggered, the signal to deliver the vasoactive or neuroactive chemical can regulate the volume, frequency, and/or pattern of vasoactive or neuroactive chemical delivered as well as the period and/or duration of the chemical stimulation. The prescribed chemical stimulus can curb a subject's appetite and/or induce anorexia, satiety, and/or weight loss in the subject.
A chemical stimulus may be triggered by a transmitter external to the human body, similar to a remote transmitter for a cardiac pacemaker. With appropriate dosing volume, frequency, and pattern, and appropriate treatment periods and duration, gastrointestinal diseases such as obesity can be treated without causing permanent injury to the surrounding tissue or organs.
Over time, stimulation, whether continuous or intermittent, whether electrical or chemical, may serve to tone the smooth muscle of the mesenteric vascular system. With sufficient tone, further stimulation may be reduced or eliminated. Thus, diseases of the gastrointestinal tract may be treated successfully using treatments of varying durations. For example, certain conditions may be treated successfully using a single treatment, while other conditions may require a more extended treatment such as, for example, one week, one month, six weeks, one year, or, in some cases, long term (including, e.g., life-long) treatment may be required.
Referring simultaneously to
In one exemplary embodiment, a subject can signal the ingestion of a meal using a remote control RF signaling device. Based on subject's desired weight loss, a microprocessor in the implanted signal generating device can send multiple trains of pulses after a preset time delay. In the case of, for example, a male subject for which a 150 pound weight loss is desired and a 1000 calorie daily diet is suggested, the preset time to start mesenteric vascular stimulation may be 10 minutes from the initiation of eating. A typical stimulation parameter can have a burst of, for example, 6 rectangular pulses of, for example, 2 msec duration and pulse amplitude of, for example, 10 mAmp. The duration of each single burst of 6 impulses may be, for example, 200 msec and have a frequency of, for example, 1 burst per second. The pulse trains may be interrupted by a quiescent phase of, for example, 800 msec. A quiescent phase may, for example, allow the mesenteric vascular musculature to repolarize. The pulse trains can induce contraction of, for example, the celiac and superior mesenteric artery, resulting in physiological obstruction to the flow of blood to the stomach and intestine. This can cause discomfort and/or pain, resulting in early satiety and/or loss of appetite in the subject.
The stimulation may continue until subject stops eating, after which the stimulation stops. Alternatively, sensors can be implanted in the gastrointestinal tract that sense ingestion of food and trigger the microprocessor which, in turn, triggers the signal generator to deliver stimulations to the celiac and superior mesenteric artery. The sensors also may detect the end of ingestion and transmit a shut off signal to the microprocessor which, in turn, will shut off the stimulator.
Based on a subject's continuing caloric restriction, the stimulation patterns can be adjusted by the subject's physician using an external remote controller without requiring additional surgery. Upon achieving desired weight loss, the stimulator can be remotely shut down and, if the subject starts gaining the weight back, the stimulator can be remotely turned on.
In certain embodiments, the methods described herein may be practiced using a neurostimulation system having at least one electrode set, at least one power source, and an extension connecting the power source to the electrode set. The electrode can be integrated into a lead, where the lead is a small conductor with more than one electrode integrated therein. In one embodiment, surgically implanted leads may be used including, for example, a 3587A RESUME II Lead, 3986 RESUME TL Lead, 3998 SPECIFY Lead, 3999 Hinged SPECIFY Lead, 3982 SYMMIX Lead, and/or 3987 On-Point PNS Lead (all from Medtronic, Inc., Minneapolis, Minn.), or any other quadripolar leads with plate electrodes capable of creating multiple stimulation combinations over a broad area of paresthesia.
In one embodiment, device 26, 36, 36′, 46, 56 may be an implantable battery-powered neurostimulator with non-invasive programmability, such as, for example, an ITREL 3, a SYNERGY, a SYNERGYPLUS+, or a SYNERGYCOMPACT+ (all from Medtronic, Inc., Minneapolis, Minn.). Alternatively, the device 26, 46′, 55 comprises a radio-frequency (RF) system, which can include an implanted receiver that detects radio-frequency signals through the skin from an external power source or transmitter such as MATTRIX transmitters (Medtronic, Inc., Minneapolis, Minn.).
In another embodiment, the extension may be a small conductor that electrically connects the power source to the lead. Exemplary extensions include low profile, low impedance extensions and/or bifurcated, low profile, low impedance extensions.
As shown in
Upon sensing an appropriate physiological stimulus, the sensing electrodes 24, 34, 44, 54 can transmit a signal to the device 26, 36, 46, 56, via wire or lead 29, 39, 49, 59 and processor 22, 32, 42, 52. The device 26, 36, 46, 56 may then begin, maintain, modulate, or stop electrical stimulation signal sent to the electrode set 21. Thus, the methods described herein can be more responsive to a subject's particular biological state and precisely modulate at least a portion of the mesenteric vasculature so that a part or the whole of the mesenteric system can contract or relax, thereby regulating the flow of blood into the gastrointestinal tract. Controlling the flow of blood into the gastrointestinal tract can also be achieved by turning off the transmitter of the external pacer. The stimulating electrode set 21 can be used in combination with additional pacing electrodes, as are known in the art, to treat disorders of gastrointestinal motility or function. It should be appreciated that the sensing electrodes can be implemented in any of the embodiments of this invention, including those depicted in
Any of the stimulating or sensing electrode sets can be placed by conventional surgical, laparoscopic, endoscopic, radiological, or other minimally invasive vascular and surgical techniques to place the desired device or devices on or adjacent to or in communication with the structure with which it is to be associated. Conventional electrode stimulation devices may be used to practice the methods described herein.
It should be appreciated that where a cardiovascular condition, such as angina, is being treated, periods of stimulation may last much longer than in treating conditions related to inducing satiety or curbing a subject's appetite. In one embodiment, the treatment of angina would be effectuated by stimulating both the celiac and SMA arteries, as described above, concurrently for a period of several hours, such as 2, 3, 4, 5, 6, or more, after a meal.
The present invention is illustrated by the following examples. It is to be understood that the particular examples, materials, amounts, and procedures are to be interpreted broadly in accordance with the scope and spirit of the invention as set forth herein.
A mesenteric electrical stimulator is laparoscopically implanted into an adult male subject. The stimulator leads are implanted on the external surface of the celiac and superior mesenteric artery and the microcontroller is implanted in a pocket in the anterior abdominal wall.
Using remote control signals, the microcontroller sends multiple bursts of 10 rectangular pulses after a preset time delay of 10 minutes from the beginning of the meal. The microcontroller sends electrical stimuli having a pulse amplitude of 10 mAmp and a burst frequency of 2 bursts per second. The pulse trains are interrupted by a quiescent phase of 500 milliseconds (msec). The stimulation is carried out until patient stops eating after which the stimulation stops.
In acute experiments, mesenteric vascular stimulation is implanted into the mesenteric vasculature of a pig. The stimulator leads are implanted on the external surface of the celiac and superior mesenteric artery and is controlled by an external microcontroller. A typical stimulation parameter can have a burst of 10 pulses with a pulse amplitude of 20 mAmp and a burst frequency of 0.5 bursts per second. The duration of each bursts of 10 pulses is 400 msec with quiescent phase of 1600 msec to allow for repolarization of the mesenteric vascular muscle. The pulse trains will induce contraction of the celiac and superior mesenteric artery resulting in physiological obstruction to the flow of blood to the stomach and intestine. The decrease in the blood flow can be measured using a Doppler flow meter.
For chronic survival experiments, the stimulator is implanted into the mesenteric vasculature of the pig. The stimulator leads are implanted on the external surface of the celiac and superior mesenteric artery and the microcontroller is implanted in a pocket in the anterior abdominal wall or worn on a jacket or belt. A typical stimulation parameter can have a burst of 10 pulses with a pulse amplitude of 10 mAmp, duration of 400 msec and a burst frequency of 0.5 bursts per second. The burst trains are interrupted by a quiescent phase of 1600 msec to allow for repolarization of the mesenteric vascular muscle. The stimulator is turned on and off randomly and the food intake during on periods is compared to off period documenting lower food and calorie intake when the stimulator is on. In addition stimulator can be turned on continuously. The animal is allowed to free feed. Serial weight measures shows less weight gain or weight loss compared to free fed animals that do not have the stimulator turned on.
Preventing, Treating, and/or Controlling Hemorrhages
In various embodiments, the present specification provides a method for regulating blood flow for treating a hemorrhage or preventing an anticipated hemorrhage. Generally, the control of blood flow through arteries and veins is accomplished by administering a stimulus to either the vessels that supply blood or nerves that control those blood vessels. The vessel or the nerve can be stimulated directly or indirectly. In various embodiments, one or more electrodes of a stimulation apparatus is placed proximate, or in electrical communication with, an artery supplying blood to the body organ, a vein supplying blood from the body organ, a nerve supplying said artery or said vein, or a wall of said body organ. In various embodiments, proximate, or in electrical communication with, is defined as a location at a distance ranging from 0 to 5 cm from a target artery supplying blood to the body organ, a vein supplying blood from the body organ, a nerve supplying said artery or said vein, or a wall of said body organ. In various embodiments, the location is also at least 1 cm upstream from a hemorrhage or a position on a blood vessel where a hemorrhage is expected to occur. In other words, in various embodiments, the preferred stimulation site at least 1 cm proximal to, or upstream from, the site of injury or operation.
In an embodiment, the present specification provides a method of modulating blood flow to an organ by applying an electrode proximate to an artery, a vein, or a nerve supplying an artery and vein corresponding to the organ, and activating the electrode to provide an electrical stimulus constricting the artery or vein. In various embodiments, providing electrical stimulation may be used to treat hemorrhage, control/stop bleeding, and treat tumors.
In some embodiments, the presently disclosed methods for treating, controlling, or preventing a hemorrhage are only practiced in high risk patients, including patients with liver disease, patients having blood coagulation disorders, or patients on anticoagulant medications, such as aspirin, Plavix, Coumadin, and/or Xarelto. In some embodiments, the presently disclosed methods are practiced in certain surgeries where the risk of causing a hemorrhage is high, including hepatobiliary surgery, having a risk of a hemorrhage in the hepatic artery and/or portal vein, a splenectomy having a risk of a hemorrhage in the splenic vein, a vascular tumor resection having a risk of a hemorrhage in the feeding tumor artery, a Whipple procedure having a risk of hemorrhage in the pancreaticoduodenal artery, a femoral-popliteal bypass having a risk of hemorrhage in the femoral artery and an aortic dissection having a risk of hemorrhage in the aorta. The methods disclosed herein are practiced in order to minimize, prevent, control, or treat a hemorrhage occurring in each of the above listed artery or vein locations.
Microsecond or millisecond electrical pulses can induce vasoconstriction within a few seconds, in both arteries and veins. Upon termination of stimulation, the blood vessels dilate back to their original size within a few minutes. This reversible vasoconstriction may be repeated without causing any tissue damage. Upon stronger stimulation, a permanent blood clot may form, completely blocking the lumen of the blood vessel. Both the reversible vasoconstriction and irreversible clotting offer a powerful approach to hemorrhage prevention and/or control in non-compressible wounds. The extent of perfusion can be controlled by varying the amplitude, pulse duration, and pulse repetition rate.
The therapeutic basis of electro-surgery is the production of heat at the cellular level. A high frequency alternating current >100 KHz (˜350K Hz) flowing through a tissue produces heat and the duty cycle of the current is used to create a desired tissue effect of cutting or coagulation. A temperature of 104° F. causes reversible cell trauma while a temperature of 120° F. causes irreversible cell trauma. Higher temperatures cause further changes in body tissues. For example, 158° F. causes coagulation, 212° F. causes a cutting effect and 392° F. causes carbonization fulguration. However, stimulating a tissue with a lower frequency (<100 KHz) electrical current produces neural stimulation without producing heat.
Conventional thermal coagulation of blood vessels typically requires tens of watts of power delivered by electrocautery or RF coagulator. Such techniques cause significant tissue injury and are not efficient in coagulation of large vessels. Typically, large vessels require mechanical ligation under direct visualization. Newer techniques, such as Ligasure, can thermally seal larger arteries, but they require bulky power supply, good visualization of the vessel and access to the vessel from all sides for accurate positioning of the surgical probe, all of which prevent the use of this technology in the field. Additionally, there is significant delay in hemorrhage control due to limitations of these technologies, resulting in significant blood loss before adequate hemorrhage control can be achieved, in turn resulting in a need for blood transfusion and associated risks.
In contrast, low-power (few mW) electrical vasoconstriction helps reduce blood flow without thermal damage to the tissue, and may not require good visualization of the injured vessel for positioning of the tool. Since very low power is required for such stimulation, a small disposable device, such as a device having electrodes as described with reference to
Stimulating blood vessels with pulses of electric current causes a local constriction of both femoral and mesenteric arteries and veins as described in the preceding sections of the present specification. It has been observed that biphasic (symmetric, anodic-first square) pulses of electric current with duration of 1 millisecond per phase, having an amplitude of 250 V and a repetition rate of 10 Hz cause, within seconds, a very pronounced local constriction of both femoral and mesenteric arteries and veins.
As can be observed from
As is demonstrated by
In an experimental setup, femoral and mesenteric arteries of test subjects were cut and then some of these were subjected to electrical stimulation. The experiment illustrated that the blood loss from the cut arteries that were subjected to electrical stimulations of pre-defined amplitude for a pre-defined period was far less than the blood loss from the cut arteries that were left untreated.
In various embodiments, electrodes, such as but not limited to those described with reference to
In an embodiment, a cuff electrode is used to provide the desired stimulation to blood vessels.
In various embodiments, the cuff electrodes of the present specification are configured to apply a pressure of less than 100 mm Hg on a blood vessel in order to place the electrode in physical contact with the vessel wall without significantly occluding blood flow mechanically.
In another embodiment, a clamp electrode is used to provide the desired stimulation to blood vessels.
In an embodiment, electrical stimulation may be used for causing vasoconstriction in a blood vessel (such as an artery) before an arterial graft is performed.
In another embodiment electrical stimulation can be applied by placing an electrode proximate (or within) any of the arteries and veins shown in
Abnormal uterine bleeding (formerly, dysfunctional uterine bleeding, or DUB) is irregular uterine bleeding that occurs in the absence of recognizable pelvic pathology, general medical disease, or pregnancy. It reflects a disruption in the normal cyclic pattern of ovulatory hormonal stimulation to the endometrial lining. The bleeding is unpredictable in many ways. It may be excessively heavy or light and may be prolonged, frequent, or random.
The blood supply of the uterus is derived chiefly from the uterine arteries. These arteries arise from the hypogastric artery and swing toward the uterus where these uterine arteries divide into a descending limb and an ascending limb. The descending limb courses downward along the cervix and lateral wall of the vagina. The ascending limb passes upward alongside the uterus and continues below the fallopian tube. Frequent anterior and posterior branches go to the vagina, cervix, and uterus. In an embodiment, the present specification provides a method for treating uterine bleeding by applying electrical stimulation proximate a hypogastric artery, a uterine artery or a branch of a uterine artery or to a nerve supplying a hypogastric artery or a uterine artery to prevent uterine bleeding. In various embodiments, continuous or intermittent stimulation may be applied. In an embodiment, the applied stimulation is controlled by an algorithm that predicts the onset of menstrual bleed and applies the stimulation prior to or during the menstrual bleed to prevent a uterine bleed.
In another embodiment, a uterine hemorrhage is controlled by applying electrical stimulation to the uterine wall.
In an embodiment, an inflatable balloon catheter having surface electrodes, as is known in the art, is inserted within a uterine cavity and then inflated so that the electrodes are in contact with the uterine walls. Electric stimulation is applied to the uterine walls via the surface electrodes in order to arrest a uterine bleed.
In an embodiment, the present specification provides a method of treating a tumor by modulating blood flow to the tumor. A condition known as ischemia reperfusion leads to injury in normal organs, especially those with high metabolic rates. It is reasonable to assume that ischemia reperfusion can also lead to injury to cancerous cells which have a very high metabolic rate. However it is hard to produce reversible ischemia followed by reperfusion using standard embolization therapies which are usually irreversible. Hence, it is desirable to reversibly control blood flow to a tumor causing ischemia followed by reperfusion to produce tumor cell injury and cell death. Also, the higher metabolic rate of the cancerous cells compared to surrounding normal tissue may allow for selective damage to the cancerous cells with less damage to the surrounding noncancerous cells supplied by the same blood vessel. Intermittent mechanical clamping has shown to protect a tumor against accelerated tumor growth. Intermittent mechanical clamping has also led to protection against hepatic injury resulting from ischemia or reperfusion. However, the process of intermittent mechanical clamping is cumbersome and time consuming during a surgery. Electrical stimulation of a vascular structure by reliably and reversibly controlling the blood flow to an organ can achieve reversible electrically mediated clamping of the blood vessel. In an embodiment, the present specification provides a method of regulating blood flow to an organ during an oncological surgery by applying an electrical stimulus to a blood vessel of an organ to cause a change in the tone of the blood vessel. In an embodiment, the present specification also provides a method of regulating blood flow to the liver during a hepatobiliary surgery by applying an electrical stimulus to a hepatic artery to cause a change in the tone of the hepatic artery.
The blood flow may be modulated or changed by applying electrical stimulation to a blood vessel supplying blood to the tumor or to a nerve innervating the blood vessel supplying blood to the tumor. In case of cancerous cells, the blood supply can be changed for variable durations followed by allowing for normal blood flow resulting in reperfusion of the tumor and injury to the cancerous cells. The duration is selected by defining the duration of ischemia or altered blood flow required to cause damage to cancerous cells and the duration of ischemia or altered blood flow required to cause damage to noncancerous cells and stimulating the blood vessel for a duration lying within the two determined durations to selectively damage the cancerous cells.
For purposes of study and providing medical treatment, the liver is segmented into a plurality of segments.
In an embodiment, a hemorrhage in a liver segment may be controlled by applying electrical stimulation to one or more blood vessels supplying blood to the segment, thereby stopping the bleeding.
In another embodiment a hemorrhage in a liver segment may also be controlled by placing one or more electrodes on the surface or into the parenchyma of one or more segments of the liver and applying an electrical stimulation to the blood vessel in the liver parenchyma to stop bleeding.
In various embodiments, the electrode 1806 coupled with the lead 1804 is inserted within an intravascular catheter for placing the electrode 1806 within a blood vessel. The catheter is used to puncture the blood vessel for placing the electrode 1806 within. In an embodiment, the anchors 1802 also comprise a patch 1808 which is used to seal the puncture site at the position of entry of the catheter into the blood vessel in order to prevent bleeding or hematoma formation. In various embodiments, the patch is composed of PTFE, silicone, or of other materials known in the art for creating intravascular stent grafts. In various embodiments, the patch dimensions range from 2× to 200× the diameter of the intravascular catheter, which in turn determines the size of the puncture opening.
In an embodiment, an articulating jaw is used to provide electrical stimulation to a blood vessel in order to control a hemorrhage of the vessel. An electrostimulation device with articulating jaws may be passed through an endoscope within a patient's body and may be placed proximate a vascular structure for application of electrical stimulation to the vascular structure.
In various embodiments, one or more active or passive wireless microdevices are permanently implanted proximate a vascular structure supplying a limb of a patient. In the event of a traumatic injury to the limb, the device is activated with an external device, such as a handheld remote control device, to deliver electrical stimulation to control hemorrhage from the vascular structure as explained in the preceding sections of the specification. In various embodiments, the implantable microdevices comprise inert passive devices or active microstimulators as known in the art.
At step 2106 the electrode is activated to provide electrical stimulation for modulating blood flow to the organ being supplied by the artery or the vein. In an embodiment, the electrode is activated and the electrical stimulation is controlled via an algorithm running on a computing device coupled with the electrical pulse generator. In an embodiment, the algorithm may cause the electrode to be stimulated only upon occurrence of a bleeding in a corresponding artery, vein or organ. In another embodiment, the algorithm may induce the electrode to apply a first stimulation that causes artery/vein constriction such that a baseline blood flow greater than 50% or 75% or 90% of the maximum blood flow is maintained, and a second stimulation in case of occurrence of bleeding to decrease blood flow to less than 50%, 25% or 10% of the maximum blood flow. In other embodiments, the electrical stimulation is applied for a duration wherein, after the cessation of the electrical stimulation, the change in the blood flow is maintained for at least 1 minute. In other embodiments, electrical stimulation is applied for another duration wherein, after the cessation of the electrical stimulation, the change in the blood flow is maintained for at least 5 minutes. In other embodiments, the electrical stimulation is intermittently turned on and off to maintain adequate control on the blood flow to allow for adequate hemostasis without compromising the viability of the organs supplied by the blood vessel. The duty cycle in such a scenario ranges from 1% to 99%. In some embodiments, the ideal duty cycle ranges from 10% to 90%. In other embodiments, the stimulation parameters, including specific duty cycle, are configured to produce vasodilation.
In an embodiment, the present specification provides a method of treating a hemorrhage by applying electrical stimulation at a pre-defined location, wherein the hemorrhage site is downstream from the stimulation location. The electrical stimulation may be provided by placing an electrode (connected to an electrical pulse generator) in proximity to (or within) a blood vessel for modulating blood flow downstream to the hemorrhage site.
In various embodiments, an electrical current having a frequency of up to 1000 KHz may be used to stimulate the blood vessels without causing thermal damage to the vessel wall or coagulation. Electrical stimulation above 1000 KHz usually generates some heat which may harm the blood vessels. In an embodiment, electrical stimulation may be applied to a blood vessel supplying a body organ, causing vasoconstriction for preventing a hemorrhagic condition in the body organ during a surgical procedure. In embodiments, a vasoconstriction of less than 25% is non-therapeutic, whereas a vasoconstriction between 25% to 50% is used for preventing a hemorrhagic condition. Further, a vasoconstriction of greater than 50% is used to treat a hemorrhage.
In various embodiments, each stimulation site serves a different hemorrhage site that is downstream from the stimulation site. In exemplary embodiments, a stimulation site in an upper limb of a patient serves to modulate blood flow (and thereby treat hemorrhage conditions) in the entire limb downstream of the upper limb stimulation site. Similarly, a stimulation site in a lower limb of a patient serves to modulate blood flow (and thereby treat hemorrhage conditions) in the entire limb downstream of the lower limb stimulation site.
In an exemplary embodiment, the stimulation is applied to the femoral artery 2302 by placing therein or proximate thereto an electrode 2332 coupled with an implantable pulse generator 2334 via lead 2333. The electrode 2332, activated via the pulse generator 2334, provides electrical stimulation to constrict the femoral artery 2302 and modulate the blood flowing downstream to the hemorrhage 2330 in the popliteal artery 2302. In embodiments, the electrode 2332 may be placed in electrical communication with any viable blood vessel at a location upstream from the hemorrhage site 2330. In an embodiment, a palpable vessel area at a distance ranging between 0.5 cm and 5 cm from the skin surface is identified for placing the electrode 2332, wherein the electrode placement site is at least 1 cm from the hemorrhage site 2330.
In case of a hemorrhage in one of the veins in the leg 2300, such as the exemplary hemorrhage 2336 in the great saphenous vein 2320 as shown in
In an exemplary embodiment, the stimulation is applied to the external iliac vein 2314 by placing therein or proximate thereto an electrode 2342 coupled with an implantable pulse generator 2340 via lead 2341. The electrode 2342, activated via the pulse generator 2340, provides electrical stimulation to constrict the external iliac vein 2314 and modulate the blood flowing downstream to the hemorrhage 2336 in the greater saphenous vein 2320. In embodiments, the electrode 2342 may be placed in electrical communication with any viable blood vessel at a location upstream from the hemorrhage site 2336. In an embodiment, a palpable vessel area at a distance ranging between 0.5 and 5 cm from the skin surface is identified for placing the electrode 2342, wherein the electrode placement site is at least 1 cm from the hemorrhage site 2336.
The embodiments described with reference to
Since hemorrhages are commonly observed in the abdominal region due to surgical procedures, in embodiments, electrodes for providing electrical stimulation are placed at one or more pre-defined locations within a patient's abdominal cavity prior to a surgical procedure. During the surgical procedure, blood loss from a blood vessel may be controlled by activating an electrode placed in proximity to any blood vessel lying upstream from the hemorrhage for providing electrical stimulation, as explained with reference to
In various embodiments, the predetermined period of time to administer electrical stimulation prior to the surgical technique is equal to at least 30 seconds. In some embodiments, the electrical stimulus is administered for at least 10 seconds during the surgical technique. In some embodiments, the electrical stimulus is administered both prior to beginning said surgical technique and for the duration of the remainder of the surgery. Further, in some embodiments, for example in some high risk cases, the at least one electrode is configured to remain within the abdominal region of the patient for a period of time ranging from 1 to 7 days and the electrical stimulus is administered post-operatively to treat post-operative hemorrhage.
In other embodiments, it may be desirable to increase the blood flow in a blood vessel to treat a condition or a disease associated with a decrease in blood flow, such as peripheral vascular disease, Raynaud's disease, coronary artery disease, cerebrovascular disease, etc. In various embodiments, this is accomplished by modifying the duty cycle of the stimulation algorithm such that the electrical stimulation is delivered to the blood vessel at a duty-cycle of >25% and on >25% of the days the therapy is delivered.
The above examples are merely illustrative of the many applications of the system of present specification. Although only a few embodiments of the present invention have been described herein, it should be understood that the present invention might be embodied in many other specific forms without departing from the spirit or scope of the invention. Therefore, the present examples and embodiments are to be considered as illustrative and not restrictive, and the invention may be modified within the scope of the appended claims.
All headings are for the convenience of the reader and should not be used to limit the meaning of the text that follows the heading, unless so specified.
The present application is a division application of U.S. patent application Ser. No. 15/451,629, entitled “Methods and Apparatuses for Stimulating Blood Vessels in Order to Control, Treat, and/or Prevent a Hemorrhage” and filed on Mar. 7, 2017, which relies on U.S. Provisional Patent Application No. 62/328,303, entitled “Method and Apparatus for Stimulating Blood Vessels for Modulating Blood Flow” and filed on Apr. 27, 2016, and U.S. Provisional Patent Application No. 62/304,841, of the same title and filed on Mar. 7, 2016, for priority. U.S. patent application Ser. No. 15/451,629 is also a continuation in part application of U.S. patent application Ser. No. 14/728,630, entitled “Method and Apparatus for Stimulating the Vascular System”, filed on Jun. 2, 2015, and issued as U.S. Pat. No. 9,656,068 on May 23, 2017, which is a continuation application of U.S. patent application Ser. No. 12/575,713, of the same title, filed on Oct. 8, 2009, and issued as U.S. Pat. No. 9,079,028 on Jul. 14, 2015, which relies on U.S. Provisional Patent Application No. 61/104,054, of the same title and filed on Oct. 9, 2008, for priority. All of the aforementioned applications are incorporated herein by reference in their entirety.
| Number | Name | Date | Kind |
|---|---|---|---|
| 1696018 | Schellberg | Dec 1928 | A |
| 3628538 | Vincent | Dec 1971 | A |
| 3776221 | Mc Intyre | Dec 1973 | A |
| 3814080 | Norman | Jun 1974 | A |
| 3866613 | Kenny | Feb 1975 | A |
| 3910281 | Kletschka | Oct 1975 | A |
| 3916875 | Toch | Nov 1975 | A |
| 3938502 | Bom | Feb 1976 | A |
| 4106511 | Erlandsson | Aug 1978 | A |
| 4153059 | Fravel | May 1979 | A |
| 4222377 | Burton | Sep 1980 | A |
| 4406288 | Horwinski | Sep 1983 | A |
| 4571749 | Fischell | Feb 1986 | A |
| 4580578 | Barsom | Apr 1986 | A |
| 4607639 | Tanagho | Aug 1986 | A |
| 4731083 | Fischell | Mar 1988 | A |
| 4739764 | Lue | Apr 1988 | A |
| 4785828 | Maurer | Nov 1988 | A |
| 4792330 | Lazarus | Dec 1988 | A |
| 4846191 | Brockway | Jul 1989 | A |
| 4886070 | Demarest | Dec 1989 | A |
| 4957484 | Murtfeldt | Sep 1990 | A |
| 5188104 | Wernicke | Feb 1993 | A |
| 5231988 | Wernicke | Aug 1993 | A |
| 5263480 | Wernicke | Nov 1993 | A |
| 5290231 | Marcadis | Mar 1994 | A |
| 5305745 | Zacouto | Apr 1994 | A |
| 5345927 | Bonutti | Sep 1994 | A |
| 5387231 | Sporer | Feb 1995 | A |
| 5391143 | Kensey | Feb 1995 | A |
| 5411535 | Fujii | May 1995 | A |
| 5423872 | Cigaina | Jun 1995 | A |
| 5437284 | Trimble | Aug 1995 | A |
| 5477860 | Essen-Moller | Dec 1995 | A |
| 5484445 | Knuth | Jan 1996 | A |
| 5505201 | Grill, Jr. | Apr 1996 | A |
| 5540658 | Evans | Jul 1996 | A |
| 5556422 | Powell, III | Sep 1996 | A |
| 5562717 | Tippey | Oct 1996 | A |
| 5590649 | Caro | Jan 1997 | A |
| 5617873 | Yost | Apr 1997 | A |
| 5655548 | Nelson | Aug 1997 | A |
| 5690691 | Chen | Nov 1997 | A |
| 5702428 | Tippey | Dec 1997 | A |
| 5713371 | Sherman | Feb 1998 | A |
| 5836994 | Bourgeois | Nov 1998 | A |
| 5861014 | Familoni | Jan 1999 | A |
| 5861044 | Crenshaw | Jan 1999 | A |
| 5865744 | Lemelson | Feb 1999 | A |
| 5927282 | Lenker | Jul 1999 | A |
| 5954714 | Saadat | Sep 1999 | A |
| 5968010 | Waxman | Oct 1999 | A |
| 5984854 | Ishikawa | Nov 1999 | A |
| 6002964 | Feler | Dec 1999 | A |
| 6024704 | Meador | Feb 2000 | A |
| 6041258 | Cigaina | Mar 2000 | A |
| 6097984 | Douglas | Aug 2000 | A |
| 6106477 | Miesel | Aug 2000 | A |
| 6112123 | Kelleher | Aug 2000 | A |
| 6115637 | Lennox | Sep 2000 | A |
| 6129685 | Howard, III | Oct 2000 | A |
| 6131575 | Lenker | Oct 2000 | A |
| 6135945 | Sultan | Oct 2000 | A |
| 6210346 | Hall | Apr 2001 | B1 |
| 6238389 | Paddock | May 2001 | B1 |
| 6238423 | Bardy | May 2001 | B1 |
| 6240315 | Mo | May 2001 | B1 |
| 6243607 | Mintchev | Jun 2001 | B1 |
| 6272370 | Gillies | Aug 2001 | B1 |
| 6292695 | Webster | Sep 2001 | B1 |
| 6299583 | Eggers | Oct 2001 | B1 |
| 6321109 | Ben-Haim | Nov 2001 | B2 |
| 6321124 | Cigaina | Nov 2001 | B1 |
| 6338718 | Ogura | Jan 2002 | B1 |
| 6364834 | Reuss | Apr 2002 | B1 |
| 6368274 | Van Antwerp | Apr 2002 | B1 |
| 6370417 | Horbaschek | Apr 2002 | B1 |
| 6383142 | Gavriely | May 2002 | B1 |
| 6428467 | Benderev | Aug 2002 | B1 |
| 6449511 | Mintchev | Sep 2002 | B1 |
| 6475223 | Werp | Nov 2002 | B1 |
| 6510332 | Greenstein | Jan 2003 | B1 |
| 6535764 | Imran | Mar 2003 | B2 |
| 6542776 | Gordon | Apr 2003 | B1 |
| 6569012 | Lydon | May 2003 | B2 |
| 6587719 | Barrett | Jul 2003 | B1 |
| 6591137 | Fischell | Jul 2003 | B1 |
| 6606523 | Jenkins | Aug 2003 | B1 |
| 6609025 | Barrett | Aug 2003 | B2 |
| 6611715 | Boveja | Aug 2003 | B1 |
| 6612977 | Staskin | Sep 2003 | B2 |
| 6615084 | Cigaina | Sep 2003 | B1 |
| 6658297 | Loeb | Dec 2003 | B2 |
| 6659936 | Furness | Dec 2003 | B1 |
| 6676686 | Naganuma | Jan 2004 | B2 |
| 6678557 | Tumey | Jan 2004 | B1 |
| 6684104 | Gordon | Jan 2004 | B2 |
| 6685729 | Gonzalez | Feb 2004 | B2 |
| 6735474 | Loeb | May 2004 | B1 |
| 6741882 | Schaeffter | May 2004 | B2 |
| 6749607 | Edwards | Jun 2004 | B2 |
| 6761631 | Lydon | Jul 2004 | B2 |
| 6826428 | Chen | Nov 2004 | B1 |
| 6832114 | Whitehurst | Dec 2004 | B1 |
| 6837886 | Collins | Jan 2005 | B2 |
| 6845776 | Stack | Jan 2005 | B2 |
| 6865416 | Dev | Mar 2005 | B2 |
| 6879859 | Boveja | Apr 2005 | B1 |
| 6889076 | Cigaina | May 2005 | B2 |
| 6895278 | Gordon | May 2005 | B1 |
| 6901295 | Sharma | May 2005 | B2 |
| 6905496 | Ellman | Jun 2005 | B1 |
| 6911003 | Anderson | Jun 2005 | B2 |
| 6915165 | Forsell | Jul 2005 | B2 |
| 6918873 | Millar | Jul 2005 | B1 |
| 6934583 | Weinberg | Aug 2005 | B2 |
| 6947792 | Ben-Haim | Sep 2005 | B2 |
| 6950707 | Whitehurst | Sep 2005 | B2 |
| 6960203 | Xiao | Nov 2005 | B2 |
| 6961621 | Krishnan | Nov 2005 | B2 |
| 6970746 | Eckmiller | Nov 2005 | B2 |
| 7006871 | Darvish | Feb 2006 | B1 |
| 7025762 | Johnston | Apr 2006 | B2 |
| 7054689 | Whitehurst | May 2006 | B1 |
| 7054690 | Imran | May 2006 | B2 |
| 7076306 | Marchal | Jul 2006 | B2 |
| 7087053 | Vanney | Aug 2006 | B2 |
| 7120498 | Imran | Oct 2006 | B2 |
| 7177693 | Starkebaum | Feb 2007 | B2 |
| 7194301 | Jenkins | Mar 2007 | B2 |
| 7200443 | Faul | Apr 2007 | B2 |
| 7299091 | Barrett | Nov 2007 | B2 |
| 7310557 | Maschino | Dec 2007 | B2 |
| 7320675 | Pastore | Jan 2008 | B2 |
| 7324852 | Barolat | Jan 2008 | B2 |
| 7340306 | Barrett | Mar 2008 | B2 |
| 7373204 | Gelfand | May 2008 | B2 |
| 7418292 | Shafer | Aug 2008 | B2 |
| 7445630 | Lashinski | Nov 2008 | B2 |
| 7481759 | Whitehurst | Jan 2009 | B2 |
| 7519421 | Denker | Apr 2009 | B2 |
| 7526337 | Shuros | Apr 2009 | B2 |
| 7551964 | Dobak, III | Jun 2009 | B2 |
| 7596413 | Libbus | Sep 2009 | B2 |
| 7632234 | Manda | Dec 2009 | B2 |
| 7653438 | Deem | Jan 2010 | B2 |
| 7664548 | Amurthur | Feb 2010 | B2 |
| 7689276 | Dobak | Mar 2010 | B2 |
| 7734341 | Shuros | Jun 2010 | B2 |
| 7738961 | Sharma | Jun 2010 | B2 |
| 7761166 | Giftakis | Jul 2010 | B2 |
| 7765006 | Martino | Jul 2010 | B2 |
| 7765007 | Martino | Jul 2010 | B2 |
| 7803195 | Levy | Sep 2010 | B2 |
| 7844338 | Knudson | Nov 2010 | B2 |
| 7881797 | Griffin | Feb 2011 | B2 |
| 7894906 | Shuros | Feb 2011 | B2 |
| 7901419 | Bachmann | Mar 2011 | B2 |
| 7917208 | Yomtov | Mar 2011 | B2 |
| 7941221 | Foley | May 2011 | B2 |
| 8007507 | Waller | Aug 2011 | B2 |
| 8024035 | Dobak | Sep 2011 | B2 |
| 8126538 | Shuros | Feb 2012 | B2 |
| 8160709 | Soffer | Apr 2012 | B2 |
| 8346482 | Fernandez | Jan 2013 | B2 |
| 8447403 | Sharma | May 2013 | B2 |
| 8447404 | Sharma | May 2013 | B2 |
| 8538534 | Soffer | Sep 2013 | B2 |
| 8543210 | Sharma | Sep 2013 | B2 |
| 8594811 | Chen | Nov 2013 | B2 |
| 8628554 | Sharma | Jan 2014 | B2 |
| 8706234 | Sharma | Apr 2014 | B2 |
| 8712529 | Sharma | Apr 2014 | B2 |
| 8712530 | Sharma | Apr 2014 | B2 |
| 8761903 | Chen | Jun 2014 | B2 |
| 8798753 | Sharma | Aug 2014 | B2 |
| 8831729 | Policker | Sep 2014 | B2 |
| 8868190 | Guez | Oct 2014 | B2 |
| 9020597 | Sharma | Apr 2015 | B2 |
| 9037244 | Sharma | May 2015 | B2 |
| 9037245 | Sharma | May 2015 | B2 |
| 9061147 | Sharma | Jun 2015 | B2 |
| 9079028 | Sharma | Jul 2015 | B2 |
| 9345879 | Sharma | May 2016 | B2 |
| 9381344 | Sharma | Jul 2016 | B2 |
| 9498619 | Goode | Nov 2016 | B2 |
| 9561367 | Sharma | Feb 2017 | B2 |
| 9616225 | Sharma | Apr 2017 | B2 |
| 9623238 | Sharma | Apr 2017 | B2 |
| 9656068 | Sharma | May 2017 | B2 |
| 9682234 | Hogg | Jun 2017 | B2 |
| 9724510 | Sharma | Aug 2017 | B2 |
| 9782583 | Sharma | Oct 2017 | B2 |
| 9789309 | Sharma | Oct 2017 | B2 |
| 9827425 | Glasberg | Nov 2017 | B2 |
| 9925367 | Sharma | Mar 2018 | B2 |
| 9950160 | Sharma | Apr 2018 | B2 |
| 10376694 | Sharma | Aug 2019 | B2 |
| 10603489 | Sharma | Mar 2020 | B2 |
| 20010041831 | Starkweather | Nov 2001 | A1 |
| 20010041870 | Gillis | Nov 2001 | A1 |
| 20020016615 | Dev | Feb 2002 | A1 |
| 20020029037 | Kim | Mar 2002 | A1 |
| 20020072780 | Foley | Jun 2002 | A1 |
| 20020123674 | Plicchi | Sep 2002 | A1 |
| 20020161382 | Neisz | Oct 2002 | A1 |
| 20020165589 | Imran | Nov 2002 | A1 |
| 20020177846 | Mulier | Nov 2002 | A1 |
| 20020188253 | Gordon | Dec 2002 | A1 |
| 20030014086 | Sharma | Jan 2003 | A1 |
| 20030028232 | Camps | Feb 2003 | A1 |
| 20030036773 | Whitehurst | Feb 2003 | A1 |
| 20030040808 | Stack | Feb 2003 | A1 |
| 20030055466 | Ben-Haim | Mar 2003 | A1 |
| 20030060848 | Kieval | Mar 2003 | A1 |
| 20030088145 | Scott | May 2003 | A1 |
| 20030109935 | Geitz | Jun 2003 | A1 |
| 20030113303 | Schwartz | Jun 2003 | A1 |
| 20030114895 | Gordon | Jun 2003 | A1 |
| 20030120321 | Bumm | Jun 2003 | A1 |
| 20030144708 | Starkebaum | Jul 2003 | A1 |
| 20030195600 | Tronnes | Oct 2003 | A1 |
| 20030204185 | Sherman | Oct 2003 | A1 |
| 20030216729 | Marchitto | Nov 2003 | A1 |
| 20040015201 | Greenstein | Jan 2004 | A1 |
| 20040037986 | Houston | Feb 2004 | A1 |
| 20040039453 | Anderson | Feb 2004 | A1 |
| 20040044376 | Flesler | Mar 2004 | A1 |
| 20040059393 | Policker | Mar 2004 | A1 |
| 20040073453 | Nenov | Apr 2004 | A1 |
| 20040088022 | Chen | May 2004 | A1 |
| 20040102804 | Chin | May 2004 | A1 |
| 20040102818 | Hakky | May 2004 | A1 |
| 20040147976 | Gordon | Jul 2004 | A1 |
| 20040158297 | Gonzalez | Aug 2004 | A1 |
| 20040167583 | Knudson | Aug 2004 | A1 |
| 20040172085 | Knudson | Sep 2004 | A1 |
| 20040172102 | Leysieffer | Sep 2004 | A1 |
| 20040186544 | King | Sep 2004 | A1 |
| 20040193229 | Starkebaum | Sep 2004 | A1 |
| 20040210118 | Letort | Oct 2004 | A1 |
| 20040220682 | Levine | Nov 2004 | A1 |
| 20040230188 | Cioanta | Nov 2004 | A1 |
| 20040236382 | Dinsmoor | Nov 2004 | A1 |
| 20040236385 | Rowe | Nov 2004 | A1 |
| 20040243152 | Taylor | Dec 2004 | A1 |
| 20050070974 | Knudson | Mar 2005 | A1 |
| 20050075702 | Shafer | Apr 2005 | A1 |
| 20050095168 | Centanni | May 2005 | A1 |
| 20050113878 | Gerber | May 2005 | A1 |
| 20050143787 | Boveja | Jun 2005 | A1 |
| 20050149014 | Hauck | Jul 2005 | A1 |
| 20050149142 | Starkebaum | Jul 2005 | A1 |
| 20050149157 | Hunter | Jul 2005 | A1 |
| 20050160395 | Hughes | Jul 2005 | A1 |
| 20050187584 | Denker | Aug 2005 | A1 |
| 20050192642 | Forsell | Sep 2005 | A1 |
| 20050216069 | Cohen | Sep 2005 | A1 |
| 20050222637 | Chen | Oct 2005 | A1 |
| 20050222638 | Foley | Oct 2005 | A1 |
| 20050240239 | Boveja | Oct 2005 | A1 |
| 20050251219 | Evans | Nov 2005 | A1 |
| 20050256587 | Egan | Nov 2005 | A1 |
| 20050267440 | Herman | Dec 2005 | A1 |
| 20060036237 | Davison | Feb 2006 | A1 |
| 20060036293 | Whitehurst | Feb 2006 | A1 |
| 20060064037 | Shalon | Mar 2006 | A1 |
| 20060074449 | Denker | Apr 2006 | A1 |
| 20060074453 | Kieval | Apr 2006 | A1 |
| 20060085042 | Hastings | Apr 2006 | A1 |
| 20060106442 | Richardson | May 2006 | A1 |
| 20060116736 | Dilorenzo | Jun 2006 | A1 |
| 20060161217 | Jaax | Jul 2006 | A1 |
| 20060167498 | Dilorenzo | Jul 2006 | A1 |
| 20060200217 | Wessman | Sep 2006 | A1 |
| 20060206160 | Cigaina | Sep 2006 | A1 |
| 20060218011 | Walker | Sep 2006 | A1 |
| 20060287678 | Shafer | Dec 2006 | A1 |
| 20070016262 | Gross | Jan 2007 | A1 |
| 20070016274 | Boveja | Jan 2007 | A1 |
| 20070021650 | Rocheleau | Jan 2007 | A1 |
| 20070021731 | Garibaldi | Jan 2007 | A1 |
| 20070027484 | Guzman | Feb 2007 | A1 |
| 20070038259 | Kieval | Feb 2007 | A1 |
| 20070100367 | Quijano | May 2007 | A1 |
| 20070106337 | Errico | May 2007 | A1 |
| 20070162085 | Dilorenzo | Jul 2007 | A1 |
| 20070185535 | Libbus | Aug 2007 | A1 |
| 20070238942 | Baylor | Oct 2007 | A1 |
| 20070244520 | Ferren | Oct 2007 | A1 |
| 20070276293 | Gertner | Nov 2007 | A1 |
| 20070282376 | Shuros | Dec 2007 | A1 |
| 20070282410 | Cross | Dec 2007 | A1 |
| 20080004673 | Rossing | Jan 2008 | A1 |
| 20080021512 | Knudson | Jan 2008 | A1 |
| 20080039904 | Bulkes | Feb 2008 | A1 |
| 20080058887 | Griffin | Mar 2008 | A1 |
| 20080058891 | Ben-Haim | Mar 2008 | A1 |
| 20080065136 | Young | Mar 2008 | A1 |
| 20080097412 | Shuros | Apr 2008 | A1 |
| 20080097466 | Levine | Apr 2008 | A1 |
| 20080154191 | Gobel | Jun 2008 | A1 |
| 20080167699 | Kieval | Jul 2008 | A1 |
| 20080195171 | Sharma | Aug 2008 | A1 |
| 20080195174 | Walker | Aug 2008 | A1 |
| 20080208355 | Stack | Aug 2008 | A1 |
| 20080255678 | Cully | Oct 2008 | A1 |
| 20080281267 | Mehier | Nov 2008 | A1 |
| 20080294228 | Brooke | Nov 2008 | A1 |
| 20080300449 | Gerber | Dec 2008 | A1 |
| 20090005867 | Lefranc | Jan 2009 | A1 |
| 20090030475 | Brynelsen | Jan 2009 | A1 |
| 20090036945 | Chancellor | Feb 2009 | A1 |
| 20090054950 | Stephens | Feb 2009 | A1 |
| 20090062881 | Gross | Mar 2009 | A1 |
| 20090069803 | Starkebaum | Mar 2009 | A1 |
| 20090131993 | Rousso | May 2009 | A1 |
| 20090132001 | Soffer | May 2009 | A1 |
| 20090192570 | Jaax | Jul 2009 | A1 |
| 20090204063 | Policker | Aug 2009 | A1 |
| 20090222058 | Craggs | Sep 2009 | A1 |
| 20090222060 | Boyd | Sep 2009 | A1 |
| 20090228059 | Shuros | Sep 2009 | A1 |
| 20090264951 | Sharma | Oct 2009 | A1 |
| 20090281553 | Kalloo | Nov 2009 | A1 |
| 20100076254 | Jimenez | Mar 2010 | A1 |
| 20100094270 | Sharma | Apr 2010 | A1 |
| 20100094373 | Sharma | Apr 2010 | A1 |
| 20100114082 | Sharma | May 2010 | A1 |
| 20100114083 | Sharma | May 2010 | A1 |
| 20100256775 | Belhe | Oct 2010 | A1 |
| 20100324432 | Bjorling | Dec 2010 | A1 |
| 20110004266 | Sharma | Jan 2011 | A1 |
| 20110071589 | Starkebaum | Mar 2011 | A1 |
| 20110213437 | Armstrong | Sep 2011 | A9 |
| 20110307075 | Sharma | Dec 2011 | A1 |
| 20120150245 | Rezai | Jun 2012 | A1 |
| 20120232610 | Soffer | Sep 2012 | A1 |
| 20120265103 | Policker | Oct 2012 | A1 |
| 20130006231 | Sharma | Jan 2013 | A1 |
| 20130013084 | Birk | Jan 2013 | A1 |
| 20130030503 | Yaniv | Jan 2013 | A1 |
| 20130172882 | Hastings | Jul 2013 | A1 |
| 20130178912 | Sharma | Jul 2013 | A1 |
| 20130218229 | Sharma | Aug 2013 | A1 |
| 20130231660 | Edwards | Sep 2013 | A1 |
| 20130238066 | Boggs, II | Sep 2013 | A1 |
| 20130289446 | Stone | Oct 2013 | A1 |
| 20140058372 | Belson | Feb 2014 | A1 |
| 20140088664 | Sharma | Mar 2014 | A1 |
| 20140194917 | Sharma | Jul 2014 | A1 |
| 20140200568 | Sharma | Jul 2014 | A1 |
| 20140222106 | Sharma | Aug 2014 | A1 |
| 20140228911 | Sharma | Aug 2014 | A1 |
| 20140243593 | Goode | Aug 2014 | A1 |
| 20140243922 | Haessler | Aug 2014 | A1 |
| 20140276336 | Sharma | Sep 2014 | A1 |
| 20140309708 | Sharma | Oct 2014 | A1 |
| 20150018924 | Sharma | Jan 2015 | A1 |
| 20150057718 | Sharma | Feb 2015 | A1 |
| 20150066109 | Glasberg | Mar 2015 | A1 |
| 20150119646 | Sharma | Apr 2015 | A1 |
| 20150119869 | Sharma | Apr 2015 | A1 |
| 20150119952 | Sharma | Apr 2015 | A1 |
| 20150126990 | Sharma | May 2015 | A1 |
| 20150224310 | Sharma | Aug 2015 | A1 |
| 20150297885 | Goode | Oct 2015 | A1 |
| 20160030734 | Sharma | Feb 2016 | A1 |
| 20160303370 | Sharma | Oct 2016 | A1 |
| 20170021169 | Sharma | Jan 2017 | A1 |
| 20170036021 | Sharma | Feb 2017 | A1 |
| 20170128716 | Goode | May 2017 | A1 |
| 20170165483 | Sharma | Jun 2017 | A1 |
| 20170296813 | Sharma | Oct 2017 | A1 |
| 20170296814 | Sharma | Oct 2017 | A1 |
| 20170361092 | Sharma | Dec 2017 | A1 |
| 20180085576 | Sharma | Mar 2018 | A1 |
| 20180154135 | Goode | Jun 2018 | A1 |
| Number | Date | Country |
|---|---|---|
| 2012242533 | Nov 2013 | AU |
| 2012250686 | Nov 2013 | AU |
| 103648582 | Mar 2014 | CN |
| 21201110038 | Jul 2012 | DE |
| 1504778 | Feb 2005 | EP |
| 2542174 | Jan 2013 | EP |
| 2696792 | Feb 2014 | EP |
| 2704791 | Mar 2014 | EP |
| 2888000 | Jul 2015 | EP |
| 3041564 | Jul 2016 | EP |
| 3071289 | Sep 2016 | EP |
| 3071291 | Sep 2016 | EP |
| 3103509 | Dec 2016 | EP |
| 3308830 | Apr 2018 | EP |
| 2655548 | Jun 1991 | FR |
| 616894 | Jan 2016 | NZ |
| 616944 | Jun 2016 | NZ |
| 1993014694 | Aug 1993 | WO |
| 1998053878 | Dec 1998 | WO |
| 2000019939 | Apr 2000 | WO |
| 2000019940 | Apr 2000 | WO |
| 2000061223 | Oct 2000 | WO |
| 2000061224 | Oct 2000 | WO |
| 0226317 | Apr 2002 | WO |
| 2003098177 | Nov 2003 | WO |
| 2004006785 | Jan 2004 | WO |
| 2004006795 | Jan 2004 | WO |
| 2004032791 | Apr 2004 | WO |
| 2005089863 | Sep 2005 | WO |
| 2006092007 | Sep 2006 | WO |
| 2007067690 | Jun 2007 | WO |
| 2007146489 | Dec 2007 | WO |
| 2007146493 | Dec 2007 | WO |
| 2007146517 | Dec 2007 | WO |
| 2008030344 | Mar 2008 | WO |
| 2008100974 | Aug 2008 | WO |
| 2009018518 | Feb 2009 | WO |
| 2009042217 | Apr 2009 | WO |
| 2009094609 | Jul 2009 | WO |
| 2009114008 | Sep 2009 | WO |
| 2010042461 | Apr 2010 | WO |
| 2010042686 | Apr 2010 | WO |
| 2011109739 | Sep 2011 | WO |
| 2011159271 | Dec 2011 | WO |
| 2012142539 | Oct 2012 | WO |
| 2012151449 | Nov 2012 | WO |
| 2012167213 | Dec 2012 | WO |
| 2013033673 | Mar 2013 | WO |
| 2013126930 | Aug 2013 | WO |
| 2014032030 | Feb 2014 | WO |
| 2014113724 | Jul 2014 | WO |
| 2014153267 | Sep 2014 | WO |
| 2015034867 | Mar 2015 | WO |
| 2015077425 | May 2015 | WO |
| 2015077435 | May 2015 | WO |
| 2016154076 | Sep 2016 | WO |
| 2016154076 | Sep 2016 | WO |
| 2017155916 | Sep 2017 | WO |
| 2018039552 | Mar 2018 | WO |
| Entry |
|---|
| International Search Report for PCT/US2008/053780, dated Jun. 8, 2009. |
| International Search Report for PCT/US2007/018631, dated Mar. 25, 2008. |
| Written Opinion for PCT/US2007/018631, dated Mar. 25, 2008. |
| International Search Report for PCT/US2007/006178, dated Dec. 5, 2008. |
| Written Opinion for PCT/US2007/006178, dated Dec. 5, 2008. |
| International Search Report for PCT/US2007/068617, dated Mar. 10, 2008. |
| Written Opinion for PCT/US2007/068617, dated Mar. 10, 2008. |
| International Search Report for PCT/US2007/066916, dated Dec. 20, 2017. |
| International Search Report for PCT/US2003/029744, dated Apr. 22, 2004. |
| International Search Report for PCT/US2003/015174, dated Apr. 27, 2004. |
| International Search Report for PCT/US2009/059609, dated Mar. 5, 2010. |
| International Search Report for PCT/US2012/040639, dated Dec. 18, 2012. |
| International Search Report for PCT/US2010/038444, dated Sep. 16, 2010. |
| International Search Report for PCT/US2009/59947, dated Feb. 12, 2010. |
| International Search Report for PCT/US2013/035031, dated Jun. 24, 2015. |
| International Search Report for PCT/US2014/012131, dated Jul. 30, 2014. |
| International Search Report for PCT/US2014/029846, dated Apr. 2, 2015. |
| International Search Report for PCT/US2009/031935, dated Jun. 15, 2009. |
| International Search Report for PCT/US2008/056479, dated Aug. 20, 2008. |
| International Search Report for PCT/2011/027243, dated Jul. 8, 2011. |
| International Search Report for PCT/US2012/033695, dated Aug. 7, 2012. |
| International Search Report for PCT/US2012/053576, dated Dec. 24, 2012. |
| International Search Report for PCT/US2013/056520, dated Apr. 4, 2014. |
| International Search Report for PCT/US2012/036408, dated Aug. 17, 2012. |
| International Search Report for PCT/US2014/066565, dated Mar. 12, 2015. |
| International Search Report for PCT/US2014/053793, dated Mar. 27, 2015. |
| International Search Report for PCT/US2014/066578, dated Mar. 19, 2015. |
| International Search Report for PCT/US2016/023327, dated Jan. 12, 2017. |
| International Search Report for PCT/US2017/048594, dated Dec. 26, 2017. |
| International Search Report for PCT/US2017/021044, dated Jul. 26, 2017. |
| Knott, E. M., et al., “Increased Lymphatic Flow in the Thoracic Duct During Manipulative Intervention”, J Am Osteopath Assoc., 105(10), (Oct. 2005), 447-456. |
| Issa, Z. F., et al., “Thoracic Spinal Cord Stimulation Reduces the Risk of Ischemic Ventricular Arrhythmias in a Postinfarction Heart Failure Canine Model”, Circulation, 111(24) (Jun. 21, 2005), 3217-3220. |
| Jameison, GG et al. “Laparoscopic Nissen Fundoplication”. Annals of Surgery, vol. 220. No. 2, p. 139 (1994). |
| Tam, WCE et al. “Delivery of radiofrequency energy to the lower esophageal sphincter and gastric cardia inhibits transient oesophageal sphincter relaxations and gastro-oesophageal reflux in patients with reflux disease”. Gut, 52(4), 479-785 (2003). |
| International Search Report for PCT/US2009/059947, dated Feb. 12, 2010. |
| Noelting et al. “Normal Values for High-Resolution Anorectal Manometry in Healthy Women: Effects of Age and Significance of Rectoanal Gradient”. Am J Gastroenterol. Oct. 2012; 107(10):1530-1536. |
| Seong et al. “Comparative analysis of summary scoring systems in measuring fecal incontinence”. J Korean Surg Soc. 2011; 81:326-331. |
| Rust et al. “The GRISS: A Psychometric Instrument for the Assessment of Sexual Dysfunction”. Articles of Sexual Behavior, vol. 15, No. 2, 1986, 157-165. |
| Infrasca, R. “Sexual Dysfunction Questionnaire: scale development and psychometric validation”. Giorn Ital Psicopat 2011; 17:253-260. |
| Althof et al. “Outcome Measurement in Female Sexual Dysfunction Clinical Trials: Review and Recommendations”. Journal of Sex & Marital Therapy, 31: 153-166, 2005. |
| Janssen et al. “Promis Sexual Function and Satisfaction Measures User Manual”, nihpromis.org; Jul. 8, 2015, 1-15. |
| Rosen et al. “The International Index of Erectile Function (IIEF)”. Sample; 1997. 1-5. |
| Ghoniem et al. “Evaluation and outcome measures in the treatment of female urinary stress incontinence: International Urogynecological Association (IUGA) guidelines for research and clinical practice”. Int Urogynecol J (2008) 19:5-33. |
| Gill et al. “Urodynamic Studies for Urinary Incontinence”, http://emedicine.medscape.com/article/1988665overview#a4; Mar. 17, 2016, 1-14. |
| Brizzolara et al., “Evidence for noradrenergic-purinergic cotransmission in the hepatic artery of the rabbit”; Br. J. Pharmacol. (1990), 99, 835-839. |
| “Miniature electrical stimulator for hemorrhage control”, Brinton et al., IEEE Trans Biomed Eng. Jun. 2014; 61(6): 1765-71. doi: 10.1109/TBME.2014.2306672 (Year: 2014). |
| Mandel Y, Manivanh R, Dalal R, et al. Vasoconstriction by electrical stimulation: new approach to control of non-compressible hemorrhage. Sci Rep. 2013;3:2111. doi: 10.1038/srep02111 (Year: 2013). |
| Number | Date | Country | |
|---|---|---|---|
| 20200269039 A1 | Aug 2020 | US |
| Number | Date | Country | |
|---|---|---|---|
| 62328303 | Apr 2016 | US | |
| 62304841 | Mar 2016 | US | |
| 61104054 | Oct 2008 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 15451629 | Mar 2017 | US |
| Child | 16793085 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 12575713 | Oct 2009 | US |
| Child | 14728630 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 14728630 | Jun 2015 | US |
| Child | 15451629 | US |
